RHR: The GLP-1 Blind Spot: What Ozempic Won’t Do for Your Metabolic Health

In this episode we discuss: How GLP-1 drugs work Proven benefits, common side effects, and discontinuation rates Emerging long-term risks of GLP-1 use The risk of nutrient deficiencies from reduced food intake Muscle loss & body composition changes Weight regain after discontinuing use The lack of root-cause treatments addressing diet, lifestyle, and metabolic drivers Who benefits most from GLP-1s vs. who may not Using GLP-1s as part of a broader health strategy Show notes: “Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis” by Berg, S., et al “Trajectory of weight regain after cessation of GLP-1 receptor agonists: A systematic review and nonlinear meta-regression” by Budini, B., et al “Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: A retrospective observational study” by Butsch, W.S., et al “Taking back control: The experience of adults using semaglutide and tirzepatide for obesity treatment – A qualitative study” by Trocchio, L.L. & Peters, F. “Glucagon-like receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks” by Gh...